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ScienceDirectThe complex heterogeneous structure of biofilms confers to
bacteria an important survival strategy. Biofilms are frequently
involved in many chronic infections in consequence of their low
susceptibility to antibiotics as well as resistance to host
defences. The increasing need of novel and effective
treatments to target these complex structures has led to a
growing interest on bacteriophages (phages) as a strategy for
biofilm control and prevention. Phages can be used alone, as a
cocktail to broaden the spectra of activity, or in combination
with other antimicrobials to improve their efficacy. Here, we
summarize the studies involving the use of phages for the
treatment or prevention of bacterial biofilms, highlighting the
biofilm features that can be tackled with phages or combined
therapy approaches.
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Introduction
Biofilms are microbial communities adhered to surfaces,
or formed on air–liquid interfaces, and are composed by
cells embedded in a self-produced polymeric matrix of
polysaccharides, proteins, nucleic acids and lipids [1].
These microbial structures are involved in many difficult
to treat chronic infections on account of their tolerance to
antibiotics and host immune defences. Accordingly, due
to the failures of antibiotic therapy toward bacterial
biofilms and also the emergence of multidrug-resistant
bacterial strains, which currently constitutes one of the
most widespread public health concerns, there is today aCurrent Opinion in Microbiology 2017, 39:48–56 renewed interest in alternative therapeutic modalities to
treat biofilm-associated infections, such as phage therapy.
Bacteriophages (phages) are natural predators of bacteria
and have been considered as a promising strategy against
bacterial biofilms. Several studies have shown that phages
can effectively infect and lyse cells present in single and
polymicrobial species biofilms [2,3], which supports the
concept of phage therapy as an alternative or complemen-
tary strategy to prevent and control biofilm-related infec-
tions. The interaction between phages and biofilms is a
rather complex process [4]. Theoretically, the close prox-
imity of cells within the biofilm structure could enhance
phage-host interaction and facilitate phage infection [5,6].
Conversely, the biofilm structure and composition as well
as the physiological state of the biofilm cells may be an
obstacle to phage infection [4]. It must be stressed that
phage/biofilm interactions are highly dependent on the
bacterial host strain, the phage characteristics, and the
biofilm structure and its composition. The biofilm forma-
tion set-up has a great impact on the biofilm character-
istics making it difficult if not impossible to withdraw
clear conclusions based on the state of art, regarding how
phages interact with biofilms and what phage character-
istics are in need to make them good biofilm controllers.
Moreover, most of the studies do not mimic real clinical
biofilms, usually formed by polymicrobial populations
and human cells. Besides, measurements of phage’s
effectiveness against biofilms is based on the overall
outcome of phage infection. There is a limited knowledge
of how phages interact with the different population of
bacterial cells that compose the biofilm. So, this review is
restricted to the current knowledge of how phages inter-
act with biofilms alone or combined with other antibiofilm
approaches highlighting the limitations as well as the
strategies that can be used to overcome biofilm barriers
and enhance phage therapy.
Limitations of bacteriophages when used as
anti-biofilm agents
It is well known that phages are currently considered as
promising antimicrobial agents for biofilm prevention and
control [7,8]. Nonetheless, although several studies have
reported significant reductions in mono and dual-species
biofilms after phage treatment [2,3,9–12], the complete
eradication of biofilms is an almost impossible task [13].
Phages need to reach their host bacteria and attach to
specific receptors located at cell surfaces before infectionwww.sciencedirect.com
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to host receptors in planktonic cultures is easier, since the
receptors are fully available for phage docking and not
surrounded by a matrix as found in biofilm cells. The
biofilm matrix, the reduced metabolic activity of biofilm
cells and the proliferation of phage-resistant phenotypes
within the biofilm are some of the major challenges to the
application of phage therapy for biofilm control.
Diffusional limitation through the biofilm matrix
It is estimated that only 10% of biofilm dry biomass are
cells. The biofilm matrix comprises the other 90% and it is
composed by different types of polymers, also known as
extracellular polymeric substances (EPS), which are
responsible for forming complex three-dimensional struc-
tures involved in the adhesion and cohesion of the bio-
films [14]. The EPS matrix has been considered as one of
the main obstacles that limits the diffusion of antimicro-
bial agents, including phages, to the bacterial cells
embedded in the biofilm [14].
Biofilm matrix is a reservoir of microbial enzymes
secreted or released upon cell lysis (such as amidases
and peptidases) that can lead to phage inactivation
[14,15]. Biofilms are also composed by dead cells that
can anchor phages and, in case of adsorbing to dead cells
receptors, phages will not be able to infect living cells.
Phages may also interact with some components of the
matrix, namely with proteins, lipopolysaccharides, poly-
saccharides and teichoic acids [16,17], which ultimately
may limit phage access to biofilm cells.
Phage diffusion through the biofilm matrix can be influ-
enced by both phage morphology and biofilm density.
Generally, the diffusion of phages through denser bio-
films will be more difficult than through less dense
biofilms [18]. Phage diffusion is also dependent on the
biofilm architecture, and it is known that biofilms can
exhibit different 3D shapes (mushroom-like, pillar-like,
hilly, or flat multicellular structures) [19] that can be
bathed by water channels making these biofilms, in
theory, more prone to phage attack than dense biofilm
structures. A recent study using LNA-FISH probes to
image phage-biofilm interaction showed that phage
infected cells were primarily located on the edges of
water channels [20].
Reduced metabolic activity of biofilm bacterial cells
The physiological state of cells has a great influence on
phage replication since exponential-phase cells are more
rapidly lysed than stationary-phase bacteria [21]. When a
bacterial culture is under nutrient limitation, there is a
transition between exponential to slow or no growth,
which is commonly also observed in mature biofilms
[22]. In biofilms, cells inhabiting the deeper layers and
under oxygen and nutrient depletion conditions [5], have
reduced metabolic activity constituting one of the mainwww.sciencedirect.com reasons why phages replicate faster in planktonic than
biofilm cells. This physiological change is linked to the
increased resistance or tolerance of biofilms to antibiotics,
since the majority of antibiotics have no activity or
impaired activity against non-dividing cells [22].
Although phages have activity against some bacterial host
cells growing under nutrient limitation, their growth
parameters are strongly influenced by the physiological
state of the host cells [23,24]. For instance, nutrient
limitations of Escherichia coli cells resulted in severe
inhibition of lytic development of phages l, P1 and T4
[23]. More recently, Bryan et al. showed that the infection
of stationary E. coli cells by the T4 phage at low MOIs did
not progress until nutrient addition. These authors
hypothesised that T4 responds to the starvation state
of E. coli by entering what, the authors call a ‘hibernation’
mode, in which T4 initiates protein synthesis but arrests
further phage development [24]. The impaired activity
of phages against stationary-phase cells has also been
reported for phages infecting other bacterial species, such
as Pseudomonas fluorescens [25], Klebsiella pneumoniae [26]
and Staphylococcus epidermidis [27]. The amount of cells
with reduced metabolic activity within biofilms are
expected to increase throughout biofilm maturation, con-
sequently older biofilms will be more difficult to tackle
that young biofilms.
In literature there is a misconception about dormancy,
persistence and stationary cells. It is often referred that
part of the biofilm population is composed by dormant
cells, which are cells that persist without division for
extended periods [28]. This type of population is also
part of suspended cultures and the number of dormant
cells increases with the age of population, being very high
in stationary growth cultures. Bacterial cells that persist
after antibiotic treatment without undergoing genetic
changes and revert to sensitive when cultured, are called
persisters [29]. To the authors knowledge, there are no
phage studies against persisters or dormant cells, there-
fore it would be important to fulfil this gap in order to
better understand the interaction between phages and
biofilms.
Development of phage resistant sub-population within
the biofilm
Phage resistance mechanisms are crucial for bacterial
survival in a set of different ecological niches. The four
main resistance mechanisms described so far are: (i)
prevention of phage DNA integration by superinfection
exclusion systems; (ii) degradation of phage DNA by
restriction-modification systems or by CRISPR-Cas sys-
tems; (iii) use of abortive infection systems that block
phage replication, transcription or translation; and (iv)
prevention of phage adsorption by loss or structural
modifications of bacterial receptors, and/or masking
phage receptor molecules by physical barriers such asCurrent Opinion in Microbiology 2017, 39:48–56
50 Antimicrobialsthe EPS matrix [30]. These mechanisms enable a quick
adaptation of bacteria to the presence of phages and
consequently, the emergence of phage-resistant mutants
is almost inevitable.
Several studies have reported that the initial reduction of
biofilm cells caused by phage treatment is usually fol-
lowed by a fast proliferation of phage-resistant sub-popu-
lations within a short period of time [10,31–34]. For
instance, the arising of phage-resistant bacterial variants
resulting from P. aeruginosa biofilm treatment with phages
was already reported [10,31]. Fu et al. studied the effect of
lytic phages in the prevention of P. aeruginosa biofilm
formation in hydrogel-coated catheters [10]. Although a
reduction in biofilm formation was observed in the first
24 h comparatively to untreated catheters, a regrow of
biofilms was observed between 24 and 48 h, and phage-
resistant biofilm isolates were recovered [10]. Phage-
resistant bacteria was also observed in Serratia marcescens
biofilms after 24 h of contact with phage [35]. In a study
developed by Oechslin et al., the genomic profile of two P.
aeruginosa phage-resistant strains was analysed and
revealed mutations in genes encoding phage receptors,
namely pilT and galU, when compared to the wild-type
strain [36]. The same was reported by Pires et al. in which
the authors described that mutations affecting the galU
gene and the pil genes were responsible for bacterial
resistance to phages [13]. This fact can be a consequence
of the endogenous oxidative stress suffered by biofilm
cells that leads to DNA damage within biofilms resulting
in the development of genetic variants with high adapt-
ability to external conditions [37,38].
Quorum sensing inhibits phage infection of biofilms
Quorum sensing (QS) is a chemical communication pro-
cess that bacteria use to regulate collective behaviours.
Accordingly, QS molecules secreted by individual bacte-
ria accumulates in dense bacterial populations enabling
bacterial cells to recognise the population density and
activate the corresponding response. QS is particularly
important to regulate biofilm physiology and therefore
believed to have a great impact in a biofilm population
regulating virulence, growth and dispersion [39]. QS can
be involved in the anti-phage process by reducing the
phage receptor numbers on the cell surface as described
for E. coli and Vibrio anguillarum [40,41]. In the case of E.
coli, the number of receptors displayed at the bacterial
surface for l phage docking is reduced in response to N-
acyl-l-homoserine lactone (AHL) quorum-sensing sig-
nals, causing a 2-fold reduction in the phage adsorption
rate [40]. For V. anguillarum a similar mechanism was
described. In this case, in high cell culture densities, a QS
mediated down regulation of ompK, the KVP40 receptor,
was observed and rendered individual cells almost unsus-
ceptible to phage infection [41]. Qin et al. observed an
increased infection efficiency of the P. aeruginosa phage
K5 in the presence of penicillic acid, a QS inhibitor [42].Current Opinion in Microbiology 2017, 39:48–56 In this work the authors did not find any alterations in
phage adsorption rateand expression of cell receptors.
According to the authors, this enhanced activity was prob-
ably due to an improved metabolic state of the cells [42].
QS mediated defensive mechanism can be a consequence
of the biofilm phenotype itself, in which part of the cells
exhibits a low metabolic state as a means to ensure efficient
energy and resources to the biofilm population, which is
controlled by QS mechanisms. Nevertheless, QS mediated
mechanisms of defence to phages need to be further
elucidated and described also for other species.
Strategies to enhance biofilm control by
phages
In order to circumvent phage limitations and improve
their performance for an efficient biofilm control, differ-
ent approaches, such as synergistic combinations with
other phages or antimicrobials, mechanical debridement
of biofilms, and genetic engineering of phage genomes
have been addressed (summarized in Figure 1). Some of
the most relevant studies performed in vitro are indicated
in Table 1.
Mechanical debridement
The hypothesis that a mechanical disruption of biofilms
can facilitate phage infection has been studied in in vivo
wound models. Seth et al., found that the tested phage was
not active against Staphylococcus aureus intact biofilms [55];
however, when the phage was administered after sharp
debridement, wound healing parameters assessed by his-
tological analysis improved significantly and bacterial
counts diminished [55]. In another study, using two differ-
ent diabetes mellitus animal models (rodent and porcine),
the combination of phages and debridement decreased
bacterial counts of P. aeruginosa and S. aureus, and improved
wound healing, particularly in the rodent model [56].
Overall, it can be assumed that debridement enhances
phage infection as a consequence of a better phage
accessibility to the biofilm cells. Moreover, cells released
due to debridement also become more susceptible to
phage infection [8], suggesting that this type of approach
can be valuable therapeutically.
Combined therapy with antibiotics and antiseptics
The combination of phages with other antimicrobial
agents, such as antibiotics or antiseptics, has been widely
studied. Previous studies have suggested that sublethal
concentrations of antibiotics can improve the production
and activity of virulent phages, a phenomenon called
phage-antibiotic synergy (PAS) [43,57]. The synergistic
effect of phages and antibiotics has been studied in
planktonic cultures (reviewed in [58]) and expanded
to biofilms [43,46]. For instance, Ryan et al. evaluated
the effect of a combined treatment of T4 phage and
cefotaxime in the eradication of E. coli ATCC 11303
biofilms. The combination of phage and antibioticwww.sciencedirect.com
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Schematic representation of strategies to overcome biofilm barriers using phages and combined therapies. The biofilm is represented by cells
under different metabolic conditions and susceptibility to phages (red cells: phage infected cells; green cells: metabolically active cells; orange
cells: phage-resistant variants; yellow cells: low metabolic activity).significantly enhanced the biofilm eradication compared
with antibiotic alone; for example, the use of phages
(titres of 104 and 107 PFU mL1) reduced the minimum
biofilm eradication concentration (MBEC) of cefotaxime
against E. coli biofilms by 2 and 8 folds, respectively [43].
Combinations of phages and antibiotics were also tested
against S. aureus [46] and K. pneumoniae [44] biofilms
resulting in an improved efficacy of biofilm control com-
pared to what was obtained after the use of each antimi-
crobial alone.
Nonetheless, the combination of phages with antibiotics
has not always resulted in improved biofilm removal
efficacy. For example, the lytic K. pneumoniae KPO1K2
phage was used alone or combined with ciprofloxacin to
treat K. pneumoniae biofilms and no significant differences
in biofilm removal efficacies between both treatments
were observed [45]. However, the combined therapy
significantly restricted the formation of resistant variants
compared with each treatment alone [45]. It has been
described that the order of treatment might have a great
impact on the outcome of biofilm control. Chaudhry et al.www.sciencedirect.com concluded that in most cases the use of phages before
antibiotics resulted in maximum killing of P. aeruginosa
biofilms in vitro. The combined treatment was particu-
larly effective against biofilms grown on layers of cultured
epithelial cells [59].
Besides antibiotics, the synergistic effect between phages
and antiseptics has also been studied. Using a continuous
flow system or microtiter plates, a combined therapy of
chlorine and phages revealed to be more effective in
controlling P. aeruginosa biofilm growth and removing
pre-formed biofilms than the separate use of each
therapy [48].
Combined therapy with enzymes
It was believed that depolymerases, which are polysac-
charide-degrading enzymes encoded in phage genomes,
could be potentially used by phages to circumvent the
biofilm barrier and facilitate the phage access to the host
cells [60,61]. However, the main function of depoly-
merases consists in the degradation of capsular polysac-
charides to facilitate phage adsorption [62–64,65] ratherCurrent Opinion in Microbiology 2017, 39:48–56
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Table 1
Some of the most relevant studies about the in vitro efficacy of phages against biofilms
Bacteria Phage(s) Experimental approach Results Reference
Combined therapy
E. coli T4 The antimicrobial synergy between T4 phage and
cefotaxime in the eradication of E. coli biofilms was
evaluated
The use of phages (titres of 104 and 107 PFU mL1) reduced the
MBEC of cefotaxime against E. coli biofilms by 2 and 8 folds,
respectively
[43]
K. pneumoniae Uncharacterized K. pneumoniae biofilms of different ages were subjected to
phage treatment (MOI of 0.01) in combination with
amoxicillin (512 mg/mL)
A significant reduction of the biofilm bacterial counts was
observed after combined therapy application
[44]
K. pneumoniae KPO1K2 12 h old K. pneumoniae biofilms were subjected to the
combined treatment of phage (MOI of 1) and ciprofloxacin
(1 mg/L)
No significant differences in biofilm removal efficacies between
phage treatment alone or combined with ciprofloxacin were
observed. However, the combined treatment significantly
prevented the emergence of resistant variants
[45]
S. aureus SAP-26 Phage (108 PFU) was applied together with azithromycin
(80 mg/L), vancomycin (10 mg/L), and rifampicin (0.6 mg/L)
against 24 h old S. aureus biofilms
Phage alone was able to kill approximately 28% of the biofilm
bacteria after 24 h. Azithromycin and vancomycin could kill25%
and 17%, respectively and when biofilms were treated with phage
and rifampicin 35% of the live cells remained after this
treatment. Phage/azithromycin and phage/vancomycin
treatments showed 40% and 60% cells alive after 24 h,
respectively
[46]
E. coli and
P. aeruginosa
T4 and PB-1 E. coli and P. aeruginosa 48 h biofilms were exposed to a
combination of tobramycin (2 mg/mL) and T4 phage (MOI of
0.01) or tobramycin (0.5 mg/mL) and PB-1 phage (MOI of
0.01) for 24 h, respectively
The combination of phage and antibiotic led to 99.99%
decrease on the survival of E. coli biofilms compared to the use of
tobramycin alone, while the combination of tobramycin and PB-1
on P. aeruginosa biofilms was just as effective as tobramycin
alone in decreasing biofilm cells. However, phage infection in
combination with tobramycin reduced the emergence of antibiotic
and phage resistant cells
[47]
P. aeruginosa Cocktail of RNA phages A mixture of phages and chlorine with different
concentrations was tested to control and remove P.
aeruginosa biofilms
The phage cocktail (3  107 PFU mL1) and chlorine (210 mg/L)
reduced biofilm growth by 94% and removed 88% of existing
biofilms
[48]
Phage cocktails
P. mirabilis Cocktail of two phages Catheters were pre-treated with the phage cocktail before
bacterial inoculation
A significant reduction in the number of P. mirabilis biofilm cells
was observed after 96 and 168 h of biofilm formation in phage-
coated catheters
[49]
P. mirabilis Cocktail of three phages Models mimicking either an established infection, or early
colonization the catheters, were treated with a single dose of
phage cocktail
In models simulating established infection, a single dose of phage
cocktail significantly extended the time taken for catheters to
block (3 fold), compared to untreated control In models
simulating an early stage infection, the phage cocktail completely
prevented catheter blockage and eradicated infection
[50]
P. aeruginosa Cocktail of five phages Catheters were pre-treated with a cocktail of five phages
prior to bacterial inoculation
The pretreatment of catheters with the phage cocktail resulted in a
3-log reduction of biofilm cell populations after 48 h, compared
with untreated catheters
[10]
P. aeruginosa
and P. mirabilis
Cocktail of six P. aeruginosa
phages and cocktail of four
P. mirabilis phages
Hydrogel-coated catheters were pre-treated with one or
both phage cocktails before bacterial challenge
Phage pretreatment reduced P. aeruginosa biofilm counts by
4 log10 CFU/cm
2 and P. mirabilis biofilm counts by >2 log10 CFU/
cm2 over 48 h
[2]
S. aureus Mixture of phage K and six of
its derivatives
The phage cocktail was used to prevent biofilm formation
and to remove established biofilms
Crystal violet staining assays revealed that the main reduction of
biofilm biomass occurred between 15 and 20 h after phage
treatment. Furthermore, a complete inhibition of S. aureus biofilm
formation over a period of 48 h was observed
[51]
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www.sciencedirect.com than cleavage of EPS present in biofilm matrix. These
enzymes encoded by phages can be heterologously
expressed, purified and added to planktonic bacteria
and biofilms, to degrade the capsular polysaccharides
and enhance phage killing [66–68]. Studies performed
by Cornelissen et al. showed that although Pseudomonas
putida phages encoding polysaccharide depolymerases
revealed biofilm degradation properties, the application
of the recombinantly expressed phage depolymerases or
non-infectious phage particles (UV inactivated) to bio-
films did not exhibit biofilm-degrading properties [66,67].
These studies showed that depolymerases alone were not
capable of degrading P. putida biofilms and highlighted
the role of phage amplification in biofilm degradation
[66,67]. Nonetheless, in a study developed by Gutie´rrez
et al., a depolymerase derived from a S. epidermidis phage
was expressed and applied to biofilms and, although dose-
dependent, it revealed biofilm removal properties, which
were evaluated by viable cell counting and crystal violet
staining of total biofilm biomass [69].
Phage cocktails
Multiple phages with different host ranges and targeting
different receptors can be combined in a single phage
preparation (phage cocktails) to expand their spectrum of
activity and prevent the development of phage-resistant
bacterial variants [70]. Several studies have reported the
use of this strategy to treat bacterial biofilms
[2,10,11,51,71]. For example, Fu et al. studied the pre-
vention of P. aeruginosa biofilm formation on hydrogel-
coated catheters pre-treated with phages [10]. In that
work, a cocktail of 5 phages was developed after evaluat-
ing their efficacy against phage-resistant biofilm variants
recovered from single phage treated catheters. The pre-
treatment of catheters with phage cocktail resulted in a
reduction of 3 orders-of-magnitude in the number of
biofilm cells after 48 h, compared with untreated cathe-
ters [10]. According to the authors, the use of phage
cocktails could be potentially applied in indwelling med-
ical devices to prevent bacterial colonization and biofilm
formation, which might inhibit the development of bac-
terial infections. Similarly, a recent study evaluated the
potential of phage cocktails (a cocktail of six P. aeruginosa
phages and a cocktail of four Proteus mirabilis phages) to
prevent single and mixed species P. aeruginosa and P.
mirabilis biofilm formation [2]. Hydrogel-coated catheters
were pre-treated with one or both phage cocktails and
significant reductions in biofilm cell counts were observed
in both cases [2].
Phage cocktails have also been successfully used to target
S. aureus biofilms. In a biofilm prevention study, crystal
violet staining assays revealed a complete inhibition of S.
aureus biofilm formation over a period of 48 h [51]. Other
studies have used phage cocktails to treat pre-formed S.
aureus biofilms and significant biofilm biomass reductions
were also observed [9,72].Current Opinion in Microbiology 2017, 39:48–56
54 AntimicrobialsGenetic manipulation of phages
Recent advances in biotechnology and synthetic biology
fields have enabled the development of a new generation
of phages designed for specific purposes. For instance, Lu
and Collins genetically engineered the T7 phage to
express a biofilm-degrading enzyme dispersin B during
phage infection [53]. Thus, the engineered phage was
able to simultaneously kill the biofilm cells and degrade
the biofilm matrix resulting in an improved efficacy of
biofilm removal than the wild type phage [53]. After 24 h
of treatment, the engineered phage was able to reduce E.
coli TG1 biofilms by 4.5 orders-of-magnitude, which was
about 2 orders-of-magnitude better than the reduction
caused by the non-enzymatic wild type phage [53].
To understand the stability of such mutation in engi-
neered phages, Schmerer et al. studied whether the
transgene will be lost or maintained during phage repli-
cation [73]. Although the engineered enzymatic phage
was better than wild type phage in clearing short-term
biofilms, no significant differences were observed in
clearing long-term biofilms (7 days), indicating that dis-
persin B has no effect in old biofilms. However, it was
further observed that the frequency of the dispersin
transgene increased in both short-term and long-term
biofilms at least temporarily [73].
In another study reported by Lu and Collins, a filamen-
tous phage was engineered to enhance the efficacy of
antibiotic therapy [52]. The engineered phage overex-
pressed a repressor of the SOS DNA repair system in E.
coli and its application resulted in an improved activity of
antibiotics against antibiotic-resistant bacteria, persister
cells and biofilm cells [52].
Pei et al. engineered T7 phage to encode a quorum-
quenching enzyme (acyl homoserine lactonase (AHL))
that has broad-range specificity for cleaving the lactone
rings of diverse AHLs. The engineered phage was able to
degrade the AHLs from many bacteria and to inhibit the
formation of mixed-species biofilms composed by P.
aeruginosa and E. coli [54].
Conclusions
Phage therapy is an attractive option to prevent and
control biofilm related infections. Apparently, due to
the close proximity of cells, phage infection of biofilms
seems to be very efficient. However, in a closer look, the
biofilm phenotype also offers protection to cells against
phage attack. The dense biofilm matrix, the low meta-
bolic state of biofilm cells and the rapid proliferation of
phage resistant variants are some of the features that hitch
biofilm/phage interactions. Consequently, it is difficult to
efficiently control a biofilm population with only one
phage. Therefore we propose combined therapies to
overcome biofilm barriers to phage infection and geneti-
cally engineered phages with new functions to turn themCurrent Opinion in Microbiology 2017, 39:48–56 more effective biofilm controllers. Further progress is also
required to understanding of how bacterial cells respond
to different therapeutic approaches, preferentially at a
single-cell level. We consider also important to normalize
biofilm studies, using biofilm formation set-up that best
mimic real biofilm environments.
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